SCHEMBL799750

SCHEMBL799750

COc1cc(O)ccc1C(=O)/C=C/c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 1.00
CAPN1 P07384 1/20 1.00
PARP1 P09874 1/20 1.00
MAOA P21397 1/20 1.00
CTSL P07711 2/20 0.84
XDH P47989 1/20 0.82
ABCG2 Q9UNQ0 6/20 0.71
MAPT P10636 5/20 0.69
TNFRSF1A P19438 1/20 0.69
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
CYP3A4 P08684 4/20 0.67
TDP1 Q9NUW8 3/20 0.67
TP53 P04637 3/20 0.67
HPGD P15428 3/20 0.67
ALOX15 P16050 3/20 0.67
MAPK1 P28482 3/20 0.67
NFKB1 P19838 3/20 0.67
ALDH1A1 P00352 2/20 0.67
NFKB2 Q00653 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634551 1.00 MAOB (1.00) MAOBCAPN1PARP1MAOACTSL
SCHEMBL30383807 1.00 MAOB (1.00) MAOBCAPN1PARP1MAOACTSL
SCHEMBL2027068 1.00 MAOB (1.00) MAOBCAPN1PARP1MAOACTSL
SCHEMBL24283301 0.93 MAOB (0.86) MAOBCAPN1PARP1MAOACTSL
SCHEMBL25195523 0.93 MAOB (0.86) MAOBCAPN1PARP1MAOACTSL
SCHEMBL25202393 0.92 CTSL (1.00) MAOBCAPN1PARP1MAOACTSL
SCHEMBL25217879 0.91 MAOB (0.84) MAOBCAPN1PARP1MAOACTSL
SCHEMBL25214503 0.91 MAOB (0.84) MAOBCAPN1PARP1MAOACTSL
SCHEMBL21527708 0.90 XDH (1.00) MAOBCAPN1PARP1MAOACTSL
SCHEMBL21527710 0.90 XDH (1.00) MAOBCAPN1PARP1MAOACTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230029027-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. 2023-01-26 US claimed
WO-2020210810-A9 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2020-11-26 WO claimed
WO-2020210810-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2020-10-15 WO claimed
WO-2019183152-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2019-09-26 WO claimed
US-12540315-B2 Compositions and methods for using genetically modified enzymes RENEW BIOPHARMA, INC. (US) 2026-02-03 US disclosed
EP-4499222-A2 COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH Locus Solutions IPCO, LLC (US) 2025-02-05 EP disclosed
US-20240366488-A1 COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2024-11-07 US disclosed
EP-4403042-A2 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2024-07-24 EP disclosed
EP-3229612-B1 USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2024-06-26 EP disclosed
WO-2023192979-A2 COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH LOCUS SOLUTIONS IPCO, LLC (US) 2023-10-05 WO disclosed
US-20230029027-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. 2023-01-26 US disclosed
US-20210301267-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. 2021-09-30 US disclosed
US-20110306073-A1 METHOD AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES THE SAMUEL ROBERTS NOBLE FOUNDATION 2011-12-15 US disclosed
US-7966133-B2 Method of identifying a potential substrates of an O-methyltransferase THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2011-06-21 US disclosed
US-20090192720-A1 METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2009-07-30 US disclosed
US-7384759-B2 Methods and compositions for determinig enzymatic activity and specificity of chalcone O-methyltransferases THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-06-10 US disclosed
US-7384759-B2 Methods and compositions for determinig enzymatic activity and specificity of chalcone O-methyltransferases THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-06-10 US disclosed
US-20040111218-A1 Methods and compositions for determining enzymatic activity and specificity of methlytransferases SAMUEL ROBERTS NOBLE FOUNDATION, THE 2004-06-10 US disclosed
WO-2003006987-A9 METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES SALK INST FOR BIOLOGICAL STUDI (US) 2003-04-24 WO disclosed
WO-2003006987-A1 METHODS AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540315-B2 Compositions and methods for using genetically modified enzymes COASY, CYP4F3, CYP4F11 MAOB 281/4885CAPN1 3997/4885PARP1 3426/4885
US-20240366488-A1 COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH NGF, FGF1, NTRK2 MAOB 253/4885CAPN1 2202/4885PARP1 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.